Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Chronic Heart Failure

Free Subscription Articles published in Lancet Retrieve available abstracts of 38 articles: HTML format

Single Articles

June 2026
1. LUND LH, Barandiaran Aizpurua A, Bollano E, Braun O, et al
   Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study.
   Lancet. 2026 Jun 24:S0140-6736(26)00904-9. doi: 10.1016/S0140-6736(26)00904.
   PubMed     Abstract available
   
   
   January 2026
2. KELSHIKER MA, Bachtiger P, Petri CF, Nakhare S, et al
   Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial.
   Lancet. 2026 Jan 28:S0140-6736(25)02156-7. doi: 10.1016/S0140-6736(25)02156.
   PubMed     Abstract available
   
   
   
3. MENSAH GA, Prabhakaran D, Mbakwem AC, Narula J, et al
   Closing the prevention gap in heart failure: World Heart Federation.
   Lancet. 2026;407:221-222.
   PubMed    
   
   
   November 2025
4. CANNATA A, Crespo-Leiro MG, Bromage DI, Ruschitzka F, et al
   Heart failure with reduced ejection fraction.
   Lancet. 2025 Nov 27:S0140-6736(25)01851-3. doi: 10.1016/S0140-6736(25)01851.
   PubMed     Abstract available
   
   
   
5. SLIWA K, Hilfiker-Kleiner D, Damasceno A, Al Farhan H, et al
   Peripartum cardiomyopathy.
   Lancet. 2025;406:2483-2493.
   PubMed     Abstract available
   
   
   August 2025
6. KOHSAKA S, Heidenreich PA
   Vericiguat across the heart failure spectrum.
   Lancet. 2025 Aug 29:S0140-6736(25)01765-9. doi: 10.1016/S0140-6736(25)01765.
   PubMed    
   
   
   
7. BUTLER J, McMullan CJ, Anstrom KJ, Barash I, et al
   Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.
   Lancet. 2025 Aug 29:S0140-6736(25)01665-4. doi: 10.1016/S0140-6736(25)01665.
   PubMed     Abstract available
   
   
   
8. ZANNAD F, O'Connor CM, Butler J, McMullan CJ, et al
   Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.
   Lancet. 2025 Aug 29:S0140-6736(25)01682-4. doi: 10.1016/S0140-6736(25)01682.
   PubMed     Abstract available
   
   
   
9. ROSSELLO X, Prescott EIB, Kristensen AMD, Latini R, et al
   beta blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
   Lancet. 2025 Aug 29:S0140-6736(25)01592-2. doi: 10.1016/S0140-6736(25)01592.
   PubMed     Abstract available
   
   
   
10. ANDERSON CS, Hua C, Wang Z, Wang C, et al
    Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
    Lancet. 2025 Aug 28:S0140-6736(25)01485-0. doi: 10.1016/S0140-6736(25)01485.
    PubMed     Abstract available
    
    
    
11. BHATT AS, Vardeny O
    Influenza vaccination in heart failure: a shot worth taking?
    Lancet. 2025 Aug 28:S0140-6736(25)01679-4. doi: 10.1016/S0140-6736(25)01679.
    PubMed    
    
    
    
12. THE LANCET
    Heart failure: time to prioritise prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01775-1. doi: 10.1016/S0140-6736(25)01775.
    PubMed    
    
    
    
13. KHAN SS, Berwanger O, Fiuzat M, McMurray JJ, et al
    Prioritising the primary prevention of heart failure.
    Lancet. 2025 Aug 28:S0140-6736(25)01393-5. doi: 10.1016/S0140-6736(25)01393.
    PubMed     Abstract available
    
    
    
14. UDELL JA, Bahit MC, Campbell P, Butler J, et al
    Prevention of heart failure after acute myocardial infarction.
    Lancet. 2025 Aug 28:S0140-6736(25)01394-7. doi: 10.1016/S0140-6736(25)01394.
    PubMed     Abstract available
    
    
    
15. OSTROMINSKI JW, Cheng AYY, Nelson AJ, Neuen BL, et al
    Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01384-4. doi: 10.1016/S0140-6736(25)01384.
    PubMed     Abstract available
    
    
    
16. WALSH M, Collister D, Gallagher M, Mark PB, et al
    Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.
    Lancet. 2025;406:695-704.
    PubMed     Abstract available
    
    
    February 2025
17. DEANFIELD J
    Effects of semaglutide on heart failure outcomes - Author's reply.
    Lancet. 2025;405:543-544.
    PubMed    
    
    
    
18. HAN J, Shan D
    Effects of semaglutide on heart failure outcomes.
    Lancet. 2025;405:542.
    PubMed    
    
    
    
19. NEVES JS, Packer M, Ferreira JP
    Effects of semaglutide on heart failure outcomes.
    Lancet. 2025;405:542-543.
    PubMed    
    
    
    August 2024
20. RUTTEN FH, Groenewegen A
    Mineralocorticoid receptor antagonists for every patient with heart failure.
    Lancet. 2024 Aug 30:S0140-6736(24)01755-0. doi: 10.1016/S0140-6736(24)01755.
    PubMed    
    
    
    
21. JHUND PS, Talebi A, Henderson AD, Claggett BL, et al
    Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
    Lancet. 2024 Aug 30:S0140-6736(24)01733-1. doi: 10.1016/S0140-6736(24)01733.
    PubMed     Abstract available
    
    
    
22. HAGE C
    GLP-1 receptor agonists in heart failure: how far to expand use?
    Lancet. 2024 Aug 29:S0140-6736(24)01763-X. doi: 10.1016/S0140-6736(24)01763.
    PubMed    
    
    
    
23. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    PubMed     Abstract available
    
    
    
24. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    PubMed     Abstract available
    
    
    
25. VADUGANATHAN M
    GLP-1 receptor agonists in heart failure.
    Lancet. 2024;404:727-729.
    PubMed    
    
    
    April 2024
26. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
    Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
    PubMed     Abstract available
    
    
    
27. DONAL E, L'Official G, Istratoaie S
    Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
    Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
    PubMed    
    
    
    March 2024
28. KIKOINE J, Kilani N, Pitta-Gros B, Yerly P, et al
    Remote haemodynamic monitoring in patients with heart failure.
    Lancet. 2024;403:808.
    PubMed    
    
    
    
29. BRUGTS JJ, Aydin D, Clephas PRD, de Boer RA, et al
    Remote haemodynamic monitoring in patients with heart failure - Authors' reply.
    Lancet. 2024;403:808-809.
    PubMed    
    
    
    
30. KOMAMURA K, Iwase M
    Remote haemodynamic monitoring in patients with heart failure.
    Lancet. 2024;403:807-808.
    PubMed    
    
    
    February 2024
31. CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al
    Heart failure with preserved ejection fraction: everything the clinician needs to know.
    Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756.
    PubMed     Abstract available
    
    
    November 2023
32. KHAN Y, Verhaeghe N, Devleesschauwer B, Cavillot L, et al
    Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.
    Lancet. 2023;402 Suppl 1:S61.
    PubMed     Abstract available
    
    
    August 2023
33. WILKOFF BL, Filippatos G, Leclercq C, Gold MR, et al
    Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial.
    Lancet. 2023 Aug 24:S0140-6736(23)00912-1. doi: 10.1016/S0140-6736(23)00912.
    PubMed     Abstract available
    
    
    May 2023
34. ANGERMANN CE
    Remote pulmonary artery pressure monitoring in heart failure care: part of the new normal?
    Lancet. 2023 May 19:S0140-6736(23)01010-3. doi: 10.1016/S0140-6736(23)01010.
    PubMed    
    
    
    
35. BRUGTS JJ, Radhoe SP, Clephas PRD, Aydin D, et al
    Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial.
    Lancet. 2023 May 19:S0140-6736(23)00923-6. doi: 10.1016/S0140-6736(23)00923.
    PubMed     Abstract available
    
    
    April 2023
36. SCHLAICH MP, Bellet M, Weber MA, Bakris GL, et al
    Fluid retention and heart failure in the PRECISION trial - Authors' reply.
    Lancet. 2023;401:1335-1336.
    PubMed    
    
    
    
37. KOHAN DE, Heerspink HJL
    Fluid retention and heart failure in the PRECISION trial.
    Lancet. 2023;401:1335.
    PubMed    
    
    
    March 2023
38. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum